Nectar Lifesciences Limited — Updates, 31-01-2025: Press Release

Nectar Lifesciences Ltd. reported steady financial growth for Q3 FY25, achieving revenue from operations of ₹4,543.34 million, slightly higher than ₹4,521.65 million in Q3 FY24 and an improvement from ₹4,278.85 million in Q2 FY25. EBITDA rose to ₹452.83 million, up from ₹426.71 million in Q3 FY24, with a margin of 9.97%, reflecting a positive trend despite a small decline from the previous quarter.

Significantly, Profit Before Tax surged to ₹125.48 million from ₹24.57 million in Q3 FY24, with the margin improving to 2.76%. Profit After Tax reached ₹78.40 million, compared to ₹15.67 million in the same period last year, enhancing the PAT margin to 1.73%.

Looking ahead, Nectar is focused on expanding its market share, particularly in higher-margin API and formulation exports. Strategic initiatives include debt reduction to lower interest costs, and increasing production capabilities, with an EBITDA projection of ₹175-185 crore for FY25 and revenue growth of 7-10% expected in FY26. Management aims to expand sales from its formulations business to over ₹600 crore by FY28, which positions the company for a positive outlook moving forward.